Larimar Therapeutics, Inc. (LRMR) Misses Q4 EPS by 14c

Larimar Therapeutics, Inc. (NASDAQ: LRMR) reported Q4 EPS of ($0.45), $0.14 worse than the analyst estimate of ($0.31).

For earnings history and earnings-related data on Larimar Therapeutics, Inc. (LRMR) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• Home Depot (HD) call put ratio 1.5 calls to 1 put with a focus on September 330 puts into quarter results
• Phillips 66, Marathon Merger Talks Collapsed - Semafor